Sovaldi (sofosbuvir) / Gilead 
Welcome,         Profile    Billing    Logout  
 18 Diseases   22 Trials   22 Trials   2501 News 


«12...56789101112131415...2122»
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  Amino-decorated mesoporous silica nanoparticles for controlled sofosbuvir delivery. (Pubmed Central) -  Nov 19, 2020   
    Amino-decorated MSNs were deemed safe to use in Sprague-Dawley rats after 14-days exposure as confirmed by the toxicological studies. More interestingly, we achieved a 2-fold higher bioavailability of sofosbuvir in Sprague-Dawley rats in comparison with sofosbuvir alone, and the T was delayed 3-times indicating a sustained release of sofosbuvir.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal, HEOR:  Drug Costs: What Can Infectious Diseases Physicians Do? (Pubmed Central) -  Nov 14, 2020   
    More interestingly, we achieved a 2-fold higher bioavailability of sofosbuvir in Sprague-Dawley rats in comparison with sofosbuvir alone, and the T was delayed 3-times indicating a sustained release of sofosbuvir. No abstract available
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Trial completion date, Trial primary completion date:  REVOLUTIOn: Antiviral Agents Against COVID-19 Infection (clinicaltrials.gov) -  Nov 9, 2020   
    P2/3,  N=1005, Not yet recruiting, 
    Two economic evaluations on sofosbuvir suggest, in combination, that sofosbuvir cannot be considered a cost-effective treatment in three quarters of the German patient population. Trial completion date: Dec 2021 --> Apr 2021 | Trial primary completion date: Dec 2021 --> Feb 2021
  • ||||||||||  Journal:  Identification and Tracking of Antiviral Drug Combinations. (Pubmed Central) -  Nov 6, 2020   
    These results indicate that synergy is achieved when a virus-directed antiviral is combined with another virus- or host-directed agent. Finally, we present an online resource that summarizes novel and known antiviral drug combinations and their developmental status.
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma, Sovaldi (sofosbuvir) / Gilead
    Journal:  Glecaprevir/pibrentasvir+sofosbuvir: an optimal retreatment strategy in the setting of HCV NS5A resistance. (Pubmed Central) -  Nov 3, 2020   
    Given that this mutation confers resistance to first line salvage options, sofosbuvir and glecaprevir/pibrentasvir was used for 12 weeks and the patient was cured of HCV infection 12 weeks after the end of treatment. This shows that sofosbuvir and glecaprevir/pibrentasvir is a viable, effective option for second line/salvage therapy of HCV infection in the setting of resistance to NS5A inhibitors with the Y93H mutation.
  • ||||||||||  tylophora indica/asthmatica standardized extract / Oasis, Sovaldi (sofosbuvir) / Gilead
    Journal:  5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl)methyl]-L-proline Inhibits Hepatitis C Virus Entry. (Pubmed Central) -  Nov 2, 2020   
    Most importantly, O859585 in combination with IFNα and sofosbuvir exhibited synergistic effects on anti-HCV activity in primary human hepatocytes. Collectively, these data suggest that O859585 may be a novel antiviral agent for HCV therapy.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir. (Pubmed Central) -  Oct 30, 2020   
    We report here that Sofosbuvir terminated RNA resists removal by the exonuclease to a substantially higher extent than RNA terminated by Remdesivir, another drug being used as a COVID-19 therapeutic. These results offer a molecular basis supporting the current use of Sofosbuvir in combination with other drugs in COVID-19 clinical trials.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs. (Pubmed Central) -  Oct 23, 2020   
    In addition, another 10 compounds from CAS COVID-19 antiviral candidate compounds dataset are also suggested by Molecular Complex Characterizing System with potential treatment for COVID-19. Our work provides a novel strategy for the repurposing and combinations of drugs in the market and for prediction of chemical candidates with anti-COVID-19 potential.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis. (Pubmed Central) -  Oct 23, 2020   
    Our work provides a novel strategy for the repurposing and combinations of drugs in the market and for prediction of chemical candidates with anti-COVID-19 potential. The 12 weeks of treatment with emitasvir-sofosbuvir was a highly efficient and safe treatment for a wide range of patients with HCV genotype 1b infection without cirrhosis, who had not been treated or who had been treated with interferon-based regimen previously.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  Sofosbuvir directly promotes the clonogenic capability of human hepatocellular carcinoma cells. (Pubmed Central) -  Oct 22, 2020   
    The 12 weeks of treatment with emitasvir-sofosbuvir was a highly efficient and safe treatment for a wide range of patients with HCV genotype 1b infection without cirrhosis, who had not been treated or who had been treated with interferon-based regimen previously. No abstract available
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Enrollment change:  Effect of Direct-acting Antiviral Drugs on Erectile Function (clinicaltrials.gov) -  Oct 21, 2020   
    P3,  N=105, Recruiting, 
    This study improves the knowledge of genetic barrier for resistance to PIs involving RASs in chronically infected patients and its possible impact on an unsuccessful treatment outcome, information that might be crucial to upcoming decisions of incorporation of new DAAs in Brazilian guidelines of antiviral therapy against HCV infection. N=2200 --> 105
  • ||||||||||  Copegus (ribavirin) / Bausch Health, Sovaldi (sofosbuvir) / Gilead
    Journal:  Diversity of the hepatitis C virus NS5B gene during HIV co-infection. (Pubmed Central) -  Oct 21, 2020   
    These data demonstrate extensive variation across the NS5B gene. Genotypic variation may have a profound impact on HCV replication and pathogenesis and deserves careful evaluation.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovodak (daclatasvir/sofosbuvir) / Rojan Pharma
    Clinical, Journal:  Efficacy of Sovodak in the Management of Patients Co-infected with HIV/HCV. (Pubmed Central) -  Oct 20, 2020   
    For the first time, the results of the present study showed that Sovodak had high SVR12 in HCV patients co-infected with HIV. However, for a precise conclusion, there is a need for larger studies and an equal number of patients with different virus genotypes.
  • ||||||||||  Copegus (ribavirin) / Bausch Health, Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  Real life Egyptian experience of Daclatasvir plus Sofosbuvir with Ribavirin in naïve difficult to treat HCV patients. (Pubmed Central) -  Oct 11, 2020   
    The available evidence seems to suggest that combination therapy of (DCV/SOF with RBV) in the treatment of chronic HCV genotype IV naïve difficult to treat patients either cirrhotic or non-cirrhotic is safe and effective. Monitoring for clinical and laboratory hepatic parameters was the basis for these findings.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  Sofosbuvir: really meets the unmet needs for Hepatis C treatment ? (Pubmed Central) -  Oct 11, 2020   
    Efficacy of the Sofosbuvir has been established in various phase 2 and phase 3 clinical trials like PROTON, ELECTRON, FUSION, POSITRON etc. Sofosbuvir has a good safety profile with few mild to moderate adverse effects. Evidence reveals that sofosbuvir has substantial impact on the treatment of HCV.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    [VIRTUAL] TEST AND CURE INCREASE OUTREACH LINKAGE TO CARE BY USE OF HCV VIRAL LOAD REAL TIME MEASURE () -  Oct 11, 2020 - Abstract #AASLD2020AASLD_939;    
    Between 9 am and 2 pm these patients had access to measure of the hepatic fibrosis by FIBROSCAN, HCV viral load in real time by CEPHEOD Xpert HCV Viral load finger-stick samples, social interview, shared educational evaluation, collective workshops, especially harm reduction, depiction of results by hepatologist and prescription of DAA (sofosbuvir velpastasvir combination) allowed delivery of 1st month of treatment... Despite 3 months lost by COVID 19 pandemy,96% of positive participants were linked to care and cure with this mobile clinic model, by screening and RNA real time measure in unity of place adapted to precarious public, patients distant from system of care had access immediately to treatment.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    [VIRTUAL] LONG TERM FOLLOW-UP OF SAFETY AND EFFICACY OF SOFOSBUVIR-BASED HCV DAAS IN PEDIATRIC PATIENTS () -  Oct 11, 2020 - Abstract #AASLD2020AASLD_924;    
    P=N/A
    Interim data are reported from a 5-year registry study (NCT02510300) in pediatric patients who received treatment for chronic hepatitis C virus (HCV) infection with sofosbuvir (SOF) +ribavirin (RBV), ledipasvir/sofosbuvir (LDV/SOF) ±RBV, or sofosbuvir/velpatasvir (SOF/VEL) in a prior clinical trial. HCV treatment with the DAAs SOF, LDV/SOF and SOF/VEL resulted in durable SVR in pediatric patients aged 3 to 17 years and did not impact growth or development through a median of 3 years and up to 5 years post-treatment.
  • ||||||||||  pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
    [VIRTUAL] DRUG-DRUG INTERACTIONS (DDIS) UNDER HCV THERAPY: ANTIPSYCHOTIC DRUGS IN ADDICTED PATIENTS AND PATIENTS ON OPIOID SUBSTITUTION THERAPY (OST) () -  Oct 11, 2020 - Abstract #AASLD2020AASLD_903;    
    In particular for the neuroleptic quetiapine, which has an interaction potential with some HCV drugs, the number of prescriptions under HCV therapy decreases - and here especially under GLE/PIB and ELB/GZP therapy, indicating that potential interactions are taken into account in the clinical routine of HCV therapy. In mentally ill addicted patients, it is important to pay particular attention to DDIs in the context of their comedications when starting HCV therapy.
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD), Copegus (ribavirin) / Bausch Health, Sovaldi (sofosbuvir) / Gilead
    [VIRTUAL] HIGH HCV CURE RATES WITH APPROVED INTERFERON-FREE DIRECT ACTING ANTIVIRALS AMONG DIVERSE MAINLAND CHINESE PATIENTS INCLUDING GENOTYPES 3a AND 3b () -  Oct 11, 2020 - Abstract #AASLD2020AASLD_874;    
    Commonly used regimens (about one-fifth each) were paritaprevir/ritonavir, ombitasvir + dasabuvir combination (n=194, 22.6%), sofosbuvir (SOF) + ribavirin (RBV) combination (n=182, 21∙2%), SOF/velpatasvir (VEL) combination ± RBV (n=172, 20.1%) and elbasvir/grazoprevir combination (n=151, 17.6%). In real-world Chinese patients with diverse GTs, Chinese FDA-approved interferon-free DAAs were well-tolerated, provided high cure rates (98.0% overall) including GT3a/b, and led to improvement of liver function.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    [VIRTUAL] Economic- and Outcomes-Related VALUE of Sofosbuvir-Based Regimens for Chronic Hepatitis C in Spain () -  Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1052;    
    Besides, SOF-based regimens gained 310,765/QALYs, saving €274 million, considering drugs, monitoring, and disease management. CONCLUSIONS : SOF-based regimens achieve significant clinical outcomes maximizing the value for HCV patients and contributing to the WHO goal, while decreasing the economic disease burden and generating significant savings to the ish NHS.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  Early fibrosis regression by shear wave elastography after successful direct-acting anti-HCV therapy. (Pubmed Central) -  Oct 2, 2020   
    To assess liver fibrosis by SWE before and after direct-acting antiviral treatment of chronic hepatitis C (CHC), we enrolled 165 CHC genotype 4 Egyptian patients treated with different Sofosbuvir-based regimens...There is early liver fibrosis regression at EOT and throughout the time after successful treatment with direct-acting antiviral agents (DAAs). SWE is a feasible, easily applicable noninvasive relatively inexpensive assessment method of liver fibrosis.